Skip to main content

Welcome to the Injection-Free

Revolution

Declare your independence.
Put CeQur Simplicity™ on your side.

Finally! A Mealtime Insulin Patch Designed to Keep Up with Your Life.

Finally! A Mealtime Insulin Patch Designed to

Keep Up with Your Life.

Fewer painful injections
Less hassle at mealtime
Easier than a pen
Discreet dosing
Improved glucose control
Encourages adherence
Better time in range
Thin and lightweight
Simple and easy to use

On-Demand, Wearable Insulin with CeQur Simplicity on Your Side.

On-Demand, Wearable Insulin with

CeQur Simplicity on Your Side

Convenient

One click delivers two units of rapid-acting insulin

Discreet

Compact, lightweight, and easily hidden under your clothes1

Injection-Free

Soft cannula, no pain, no hassle1

CeQur Simplicity is a revolutionary patch that delivers injection-free mealtime insulin. It’s not a pen. It’s not a pump. It’s a wearable insulin patch! Using a tiny, flexible cannula, you can deliver rapid-acting insulin under your skin. It changes the way you dose for meals and correction boluses, eliminating the need for multiple daily injections.3
CeQur Simplicity is a revolutionary patch that delivers injection-free mealtime insulin. It’s not a pen. It’s not a pump. It’s a wearable insulin patch! Using a tiny, flexible cannula, you can deliver rapid-acting insulin under your skin. It changes the way you dose for meals and correction boluses, eliminating the need for multiple daily injections.3

Easy Insulin

With CeQur Simplicity, you can click and dose in any situation. There is no complicated programming, no reliance on digital technology, and no exposed tubing. It’s simple, on-demand, one-click dosing for mealtime insulin and bolus correction.

Comfortable to Wear

CeQur Simplicity stays in place for up to three days, no matter your activity level.5 With rounded corners, a thin, low-profile design, and a flexible cannula, it lets you forget all about it until it’s time to dose.

Ease the Burden

Say goodbye to multiple daily injections. One CeQur Simplicity patch replaces nine mealtime injections, lessening the pain and burden that can be experienced with pens and syringes.1

Safety First

There’s no guesswork. You’ll feel and hear a “click” when each 2-unit dose is given. The two-button dosing mechanism prevents accidental dosing during activities and sleep.5

CeQur Simplicity Is Clinically Shown to Keep Your A1C and Time-in-Range (TIR) in Check, Which Reduces the Risk of Long-Term Health Complications.1,2

Take back glycemic control

After 24 weeks, CeQur Simplicity users increased TIR by 50%.2

Flatten blood sugar spikes

88% of people followed their insulin regimen better using Simplicity.3

Achieve your targets

CeQur Simplicity users decreased their A1C an average of 1.7% after 24 weeks.1

CeQur Simplicity Is Clinically Shown to Keep Your A1C and Time-in-Range (TIR) in Check, Which Reduces the Risk of Long-Term Health Complications1,2

Take back glycemic control

After 24 weeks, CeQur Simplicity users increased TIR by 50%2

Flatten blood sugar spikes

88% of people followed their insulin regimen better using CeQur Simplicity3

Achieve your targets

CeQur Simplicity users decreased their A1C by an average of 1.7% after 24 weeks1

Results were comparable to pens. Consistent A1C <7% supports HEDIS Comprehensive Diabetes Care measure8

Baseline
Week 24
Week 44

Sign Up to Learn More About CeQur SimplicityTM

    We respect the importance of your privacy and understand your health is a very personal and sensitive subject. CeQur Simplicity wants you to understand how it will use the information provided by you on this registration page. By clicking the “Submit” button above, you are indicating that CeQur Simplicity or its partners may use your information for program improvements, quality monitoring, data and analytics for commercial purposes, and future marketing communications. You also understand that you may opt out from receiving any future communications from CeQur Simplicity or its partners by clicking the “unsubscribe” link within any email you receive, or by calling 1-888-552-3787.

    References
    1. Bergenstal R, Peyrot M, Dreon D, Aroda V, Bailey T, Brazg R, Frias J, Johnson M, Klonoff D, Kruger D, Ramtoola S, Rosenstock J, Serusclat P, Weinstock R, Naik R, Shearer D, Zraick V, Levy B on behalf of the Calibra Study Group. 2019. Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. Diabetes Technology and Therapeutics 21 (5):1-13.
    2. Johnson ML, Dreon DM, Levy BL, Richter S, Mullen D, Bergenstal R. 2018. Comparing Patch vs. Pen Bolus Insulin Delivery in Type 2 Diabetes Using Continuous Glucose Monitoring Metrics and Profiles. Diabetes 2018 Jul; 67(Supplement 1).
    3. Zraick V, Dreon D, Nalk R, Shearer D, Crawford S, Bradford J, Levy B. 2016. Patient User Experience Evaluation of Bolus Patch Insulin Delivery System. Poster presented at the American Diabetes Association’s 76th Scientific Sessions. Abstract 995-P. New Orleans, LA, USA.
    4. Peyrot M, Dreon D, Zraick V, Cross B, Tan MH. 2018. Patient Perceptions and Preferences for a Mealtime Insulin Delivery Patch. Diabetes Therapy. 9(1):297–307.
    5. Dreon D, Hannon T, Cross B, Carter B, Mercer N, Nguyen J, Tran A , Melendez P, Morales N, Nelson J, Tan M. 2018. Laboratory and Benchtop Performance of a Mealtime Insulin-Delivery System. Journal of Diabetes Science and Technology. 12(4):817-827.
    6. Battelino T, Danne T, Bergenstal R, Amiel S, Beck R, Biester T, Bosi E, Buckingham B, Cefalu W, Close K, Cobelli C, Dassau E, DeVries J, Donaghue K, Dovc K, Doyle F, Garg S, Grunberger G, Heller S, Heinemann L, Hirsch I, Hovorka R, Jia W, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Levine B, Mayorov A, Mathieu C, Murphy H, Nimri R, Nørgaard K, Parkin C, Renard E, Rodbard D, Saboo B, Schatz D, Stoner K, Urakami T, Weinzimer S, Phillip M. 2019. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care Aug 2019, 42 (8) 1593-1603.
    7. Bohannon N, Bergenstal R, Cuddihy R, Kruger D, List S, Massaro E, Molich M, Raskin P, Remtema H, Strowig S, Whitehouse F, Brunelle R, Dreon D, Tan M. 2011. Comparison of a Novel Insulin Bolus-Patch with Pen/Syringe Injection to Deliver Mealtime Insulin for Efficacy, Preference, and Quality of Life in Adults with Diabetes: A Randomized, Crossover, Multicenter Study. Diabetes Technology & Therapeutics. 13(10):1031-1037.
    8. 2020 HEDIS Measures summary of changes. HEDIS Measures and Technical Resources 2020  [cited 2020 March 9]; available from: https://www.ncqa.org/hedis/measures/comprehensive-diabetes-care/.
    9. Peyrot M, et al. Correlates of insulin injection omission. Diabetes Care. 2010; 33(2): p. 242-243 charts, discussion p. 244.
    10. Barry R, Johns DON, Rees B. 2329-PUB: Transitioning T2DM Patients to Basal-Bolus Insulin Leads to Sustainable A1C Improvement. Diabetes, 2019. 68(Supplement 1): p. 2329-PUB. This is a post-hoc analysis done on Bergenstal Trial.

    11. Results from standardized dQ&A patient survey. Data on file at CeQur.